Status:
COMPLETED
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
Lead Sponsor:
Daiichi Sankyo
Collaborating Sponsors:
Shanghai Sankyo Pharmaceuticals Co., Ltd.
Conditions:
Essential Hypertension
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of olmesartan medoxomil compared with losartan potassium in patients with mild to moderate essential hypertension.
Eligibility Criteria
Inclusion
- mild to moderated essential hypertension (mean seated diastolic blood pressure ≥ 95 mmHg and \<110 mmHg, mean seated systolic blood pressure \< 180 mmHg)
- able to give written informed consent
Exclusion
- known or suspected secondary hypertension
- history of chronic hepatic diseases
- obstructive hypertrophic cardiomyopathy/clinically significant valvular heart disease
- cardiac arrhythmia
- unstable angina pectoris
- congestive heart insufficiency (New York Heart Association classification III-IV)
- bilateral renal artery stenosis
- isolated renal artery stenosis
- post renal transplantation
- history of acute myocardial infarction/percutaneous transluminal coronary angioplasty or heart surgery within three months before enrollment
- retina bleeding/effusion
- insulin dependent diabetes mellitus
- uncontrolled non-insulin dependent diabetes mellitus
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2005
Estimated Enrollment :
287 Patients enrolled
Trial Details
Trial ID
NCT00856271
Start Date
August 1 2004
End Date
April 1 2005
Last Update
September 29 2010
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing, China
2
Chongqing, China
3
Guangzhou, China
4
Nanjing, China